• Ruxolitinib

    CAS: 941678-49-5
    SPEC: IHS
    Regulatory status: R&D

    넶69 ¥ 0.00

  • Aprocitentan

    CAS: 1103522-45-7
    SPEC: IHS
    Regulatory status: R&D           

    넶61 ¥ 0.00

  • Cobimetinib

    CAS: 934660-93-2
    SPEC: IHS
    Regulatory status: R&D

    넶48 ¥ 0.00

  • Futibatinib

    CAS: 1448169-71-8
    Indication: adults with a specific type of bile duct cancer called intrahepatic cholangiocarcinoma (iCCA)

    넶49 ¥ 0.00

  • Fedratinib

    CAS: 936091-26-8
    Indication: adults with intermediate-risk or high-risk myelofibrosis

    넶45 ¥ 0.00

  • Momelotinib

    CAS: 1056634-68-4
    SPEC: IHS
    Regulatory status: R&D

    넶51 ¥ 0.00

  • Olutasidenib

    CAS: 1887014-12-1
    Indication: relapsed or refractory acute myeloid leukemia (AML) in adult patients who have a susceptible isocitrate dehydrogenase-1 (IDH-1) mutation.

    넶56 ¥ 0.00